High Flow Nasal Cannula in the Emergency Department (HFNC)

March 2, 2018 updated by: Hospital Italiano de Buenos Aires

Use of High-Flow Nasal Cannula for Acute Respiratory Failure in the Emergency Department

The aim of this study was to describe the changes in respiratory rate, heart rate and dyspnea, before and after using HFNC in patients presenting to our emergency department with ARF.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A retrospective cohort study was performed. To all adults presenting to the emergency department who used high flow nasal cannula to treat clinical signs of acute respiratory failure based on the presence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis despite conventional oxygen therapy ≥ 6 l/min. Demographic variables and clinical and gasometric parameters before and after two hours using HFNC were recorded.

Study Type

Observational

Enrollment (Actual)

43

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with and without a history of lung disease who used high flow nasal cannula. We defined clinical signs of acute respiratory failure based on the presence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis, despite conventional oxygen therapy ≥ 6 l/min.

Description

Inclusion Criteria:

  • patients aged ≥ 18 years
  • attended between July 1st, 2015 and January 31st , 2017 in the Emergency Department of the Hospital Italiano de Buenos Aires
  • with clinical signs of acute respiratory failure

Exclusion Criteria:

- Pulse oximetry > 90% breathing room air

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate
Time Frame: 2 hours
The closest value of Heart Rate before starting HFNC, and two hours later was collected from the electronic clinical history.
2 hours
Respiratory Rate
Time Frame: 2 hours
The closest value of Respiratory Rate before starting HFNC, and two hours later was collected from the electronic clinical history.
2 hours
Dyspnea
Time Frame: 2 hours
The closest value of Dyspnea (Modified Borg Dyspnea scale) before starting HFNC, and two hours later was collected from the electronic clinical history. The Modified Borg Dyspnea Scale is a rated numerical score used to measure dyspnea. This scale has a minimum value of 0 ( represent no dyspnea) and a maximum value of 10 (worse dyspnea).
2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Initial HFNC setting
Time Frame: 2 hours
The gas flow rate and the fraction of inspired oxygen at the HFNC initiation of treatment were collected from the electronic clinical history.
2 hours
Acute respiratory failure etiology
Time Frame: 3 minutes
Presence of a breathing frequency ≥ 25 breath/min and increase work of breathing evidence by dyspnea, in-drawing, accessory-muscle use and/or diaphoresis despite conventional oxygen therapy ≥ 6 l/min.
3 minutes
Average time of use the HFNC
Time Frame: until 28 days
The total hours of use of HFNC were collected from the electronic clinical history.
until 28 days
Delay of HFNC treatment
Time Frame: until 24hs
The hours between the admission to HFNC initiation were collected from the electronic clinical history.
until 24hs
Efficacy of HFNC treatment
Time Frame: 28 days
When the patient did not need for escalation to other non-invasive or invasive ventilatory support.
28 days
Failure of HFNC treatment
Time Frame: 28 days
When the patient need non-invasive or invasive ventilatory support or died. The type of ventilatory support post-failure were collected from the electronic clinical history.
28 days
Mortality rate at 28 day from ED admission
Time Frame: 28 days
The number of patients who died after requiring HFNCO were collected from the electronic clinical history
28 days
Palliative Care
Time Frame: 28 days
Consensus between patient and/or patient´s family and the physician about the care for the terminally ill patient, provided by an organized health service
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Italiano de Buenos Aires

Investigators

  • Principal Investigator: Vanesa R Ruiz, RT, Hospital Italiano de Buenos Aires

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2015

Primary Completion (Actual)

January 31, 2017

Study Completion (Actual)

January 31, 2017

Study Registration Dates

First Submitted

February 20, 2018

First Submitted That Met QC Criteria

March 2, 2018

First Posted (Actual)

March 9, 2018

Study Record Updates

Last Update Posted (Actual)

March 9, 2018

Last Update Submitted That Met QC Criteria

March 2, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 3106

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Respiratory Failure

Clinical Trials on High Flow Nasal Cannula Oxygen

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe